Loading...

BeiGene, Ltd.

BGNENASDAQ
Healthcare
Biotechnology
$184.71
$0.90(0.49%)

BeiGene, Ltd. (BGNE) Stock Overview

Explore BeiGene, Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 74.4/100

Key Financials

Market Cap20.2B
P/E Ratio-50.34
EPS (TTM)$-8.19
ROE-0.12%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$140.76

BGNE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BeiGene, Ltd. (BGNE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $140.76.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -50.34 and a market capitalization of 20.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;